A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2017
Price : $35 *
At a glance
- Drugs MEDI 6469 (Primary) ; Durvalumab; Rituximab; Tremelimumab
- Indications Diffuse large B cell lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors MedImmune
- 31 Aug 2018 Biomarkers information updated
- 27 Mar 2017 Status changed from completed to discontinued.
- 02 May 2016 Status changed from active, no longer recruiting to completed.